Hexvix

Hexvix is an intravesical solution containing the active ingredient hexaminolevulinate. It is supplied as a prescription‑only diagnostic agent used in the European market. The formulation is administered directly into the bladder, where it acts as a photosensitizer to aid visualization of urothelial lesions during cystoscopic examination. Hexvix does not treat disease but assists clinicians in detecting non‑muscle invasive bladder cancer and improve diagnostic accuracy during the procedure.

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic evaluation.

- Enhances fluorescence of malignant urothelial cells under blue light, facilitating identification of carcinoma in situ. - Used in conjunction with standard white‑light cystoscopy to improve lesion detection rates. - Applied intravesically before photodynamic examination, typically after bladder irrigation. - Supports targeted biopsy by highlighting suspicious areas that may be missed with conventional imaging. - Assists in surveillance protocols for patients with a history of bladder cancer. - May be employed in combination with narrow‑band imaging to further increase diagnostic confidence.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the drug.

Common: - Mild bladder irritation or burning sensation during or after instillation. - Transient hematuria or blood‑tinged urine. - Temporary urinary urgency or frequency. - Light‑sensitivity reactions limited to the bladder mucosa, causing mild discomfort. - Mild dysuria or discomfort during urination.

Serious: - Severe allergic reaction, including anaphylaxis. - Persistent bladder inflammation or cystitis. - Significant phototoxic injury to surrounding tissues if exposed to intense light. - Acute urinary retention requiring catheterization. - Rare cases of systemic photosensitivity